These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12549943)

  • 1. Aminoglycoside-associated nephrotoxicity in the elderly.
    Baciewicz AM; Sokos DR; Cowan RI
    Ann Pharmacother; 2003 Feb; 37(2):182-6. PubMed ID: 12549943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.
    Kim MJ; Bertino JS; Erb TA; Jenkins PL; Nafziger AN
    J Clin Pharmacol; 2004 Jul; 44(7):696-707. PubMed ID: 15199074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug usage evaluation of aminoglycoside-induced nephrotoxicity in a community hospital.
    Wade WE; McCall CY
    Hosp Formul; 1990 Oct; 25(10):1092-4, 1096. PubMed ID: 10107391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice.
    Lucena MI; Andrade RJ; Cabello MR; Hidalgo R; Gonzalez-Correa JA; Sanchez de la Cuesta F
    J Hepatol; 1995 Feb; 22(2):189-96. PubMed ID: 7790708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides.
    Raveh D; Kopyt M; Hite Y; Rudensky B; Sonnenblick M; Yinnon AM
    QJM; 2002 May; 95(5):291-7. PubMed ID: 11978900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.
    Graham AC; Mercier RC; Achusim LE; Pai MP
    Ann Pharmacother; 2004 Jun; 38(6):936-41. PubMed ID: 15084688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
    Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
    Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary N-acetyl-beta-D-glucosaminidase (NAG) in aminoglycoside nephrotoxicity.
    Assadamongkol K; Tapaneya-Olarn W; Chatasingh S
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():42-6. PubMed ID: 2732646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for toxicity in elderly patients given aminoglycosides once daily.
    Paterson DL; Robson JM; Wagener MM
    J Gen Intern Med; 1998 Nov; 13(11):735-9. PubMed ID: 9824518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoglycosides use in patients over 75 years old.
    Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
    Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and predictors of vancomycin-associated nephrotoxicity.
    Moh'd H; Kheir F; Kong L; Du P; Farag H; Mohamad A; Zurlo JJ
    South Med J; 2014 Jun; 107(6):383-8. PubMed ID: 24945176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycosides: assessing the potential for nephrotoxicity.
    Wilson SE
    Surg Gynecol Obstet; 1990; 171 Suppl():24-30. PubMed ID: 2244292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients.
    van Maarseveen E; Man WH; Proost J; Neef C; Touw D
    Int J Clin Pharm; 2015 Apr; 37(2):342-7. PubMed ID: 25616626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.
    Destache CJ
    J Pharm Pract; 2014 Dec; 27(6):562-6. PubMed ID: 25124375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglycoside dosing: a randomized prospective study.
    Kemme DJ; Daniel CI
    South Med J; 1993 Jan; 86(1):46-51. PubMed ID: 8420016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aminoglygoside nephrotoxicity].
    Baykal M
    Mikrobiyol Bul; 1986 Jan; 20(1):32-6. PubMed ID: 3523171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.
    Matson KL; Shaffer CL; Beck GL; Simonsen KA
    Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
    de Jager P; van Altena R
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.
    Cies JJ; Shankar V
    Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.